Equities analysts expect Heat Biologics Inc (NASDAQ:HTBX) to announce sales of $3.32 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Heat Biologics’ earnings, with the lowest sales estimate coming in at $1.20 million and the highest estimate coming in at $6.95 million. Heat Biologics reported sales of $470,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 606.4%. The business is scheduled to announce its next earnings report on Monday, November 12th.

According to Zacks, analysts expect that Heat Biologics will report full-year sales of $6.28 million for the current year, with estimates ranging from $4.30 million to $8.40 million. For the next year, analysts expect that the business will report sales of $3.23 million, with estimates ranging from $2.40 million to $4.80 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Heat Biologics.

Heat Biologics (NASDAQ:HTBX) last announced its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.09). Heat Biologics had a negative net margin of 437.62% and a negative return on equity of 116.28%. The business had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.11 million.

A number of brokerages have weighed in on HTBX. Eurobank EFG assumed coverage on Heat Biologics in a report on Monday, July 9th. They issued a “buy” rating and a $11.00 price objective on the stock. HC Wainwright assumed coverage on shares of Heat Biologics in a research report on Tuesday, June 26th. They set a “buy” rating and a $6.00 price target for the company. Finally, Brookline Cap M reiterated a “buy” rating on shares of Heat Biologics in a research report on Wednesday, August 1st.

An institutional investor recently bought a new position in Heat Biologics stock. Northern Trust Corp purchased a new stake in shares of Heat Biologics Inc (NASDAQ:HTBX) in the second quarter, according to its most recent filing with the SEC. The firm purchased 51,512 shares of the biopharmaceutical company’s stock, valued at approximately $111,000. Northern Trust Corp owned 0.22% of Heat Biologics at the end of the most recent quarter. Hedge funds and other institutional investors own 4.41% of the company’s stock.

HTBX traded up $0.03 during trading on Friday, reaching $1.96. The company’s stock had a trading volume of 813 shares, compared to its average volume of 162,028. Heat Biologics has a 52-week low of $1.09 and a 52-week high of $7.90.

Heat Biologics Company Profile

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Further Reading: Asset Allocation

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.